Certifications
Medical Oncology
American Board of Internal Medicine
Clinical Focus
Education
Residency, Internal Medicine
Bronx-Lebanon Hospital CenterResidency, Internal Medicine
Harper HospitalFellowship, Medical Oncology
MD Anderson Cancer Center (Univ of Texas)
Biography
Sundar Jagannath, MD, is Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute. Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma — a relatively rare cancer of the bone marrow.
Prior to joining Mount Sinai, Dr. Jagannath served as chief of the multiple myeloma and transplant program at St. Vincent’s Hospital Comprehensive Cancer Center from 1998 until the hospital closed
in April 2010. The transplant program, with stored stem cells of more than 300 patients, and the myeloma program with ongoing clinical trials, have been integrated into The Tisch Cancer Institute.
Mount Sinai’s Multiple Myeloma Program provides clinical care to a large patient population, including the transfer of more than 800 patients who had been receiving care at St. Vincent’s.
Dr. Jagannath has published more than 180 peer-reviewed articles in top publications, including the New England Journal of Medicine, Blood, the Journal of Clinical Oncology and Cancer. He has presented more than 150 abstracts and authored nearly 30 book chapters.
Clinical Trials
- An Open-Label, Dose-Escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects with Multiple Myeloma
- An Open Label, Single-arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
- An open label, Single Arm, Phase 2 Study if Carfilzomib in Patients with Relapsed Multiple Myeloma
- A Phase 1/2 Multi-Center, Randomized, Open Label Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of CC-4047 Alone or in Combination with Low-Dose Dexamthasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
- Compassionate Use of Carfilzomib Maintenance Therapy in a Subject Who Previously Participated in a Carfilzomib Treatment Protocol
- A Phase 1b/2, Multicenter, Open-Label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed Multiple Myeloma
- A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients with Untreated Asymptomatic Myeloma
- A Phase I Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetcs (PK), and Safety of BT062 in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma
Industry Relationships
Physicians and scientists on the faculty of Mount Sinai School of Medicine often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Jagannath during 2011 and/or 2012. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Celgene Corporation; Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited )
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Celgene Corporation; Merck & Co., Inc.
Other Activities: Examples include participation on a Data Safety Monitoring Board (DSMB) or other committees
- PharmaMar (Zeltia Group)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://www.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
One Gustave L. Levy Place
Box 1185
New York, NY 10029
Ruttenberg Treatment Center
1190 Fifth Avenue
New York, NY 10029
